Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 15/20 | 0.68 |
| ▸ | TP53 | P04637 | 2/20 | 0.68 |
| ▸ | PKM | P14618 | 2/20 | 0.68 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.68 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.68 |
| ▸ | RELA | Q04206 | 2/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.56 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6000790 | 0.89 | MRGPRX4 (0.68) | MRGPRX4TP53PKMNFKB1NFKB2 | |
| SCHEMBL3312463 | 0.87 | MRGPRX4 (0.60) | MRGPRX4TP53PKMNFKB1NFKB2 | |
| SCHEMBL27650204 | 0.86 | NR4A2 (0.65) | MRGPRX4TP53PKMNFKB1NFKB2 | |
| SCHEMBL19301712 | 0.85 | MRGPRX4 (0.58) | MRGPRX4TP53PKMNFKB1NFKB2 | |
| Ether SCHEMBL7811293 | 0.85 | MRGPRX4 (0.57) | MRGPRX4TP53PKMNFKB1NFKB2 | |
| SCHEMBL14283958 | 0.85 | PARP1 (0.50) | MRGPRX4TP53PKMNFKB1NFKB2 | |
| SCHEMBL14093309 | 0.84 | PLA2G4B (0.67) | MRGPRX4TP53PKMNFKB1NFKB2 | |
| Isophthalic Acid SCHEMBL1557618 | 0.83 | KMT2A (0.56) | MRGPRX4TP53PKMNFKB1NFKB2 | |
| SCHEMBL25284732 | 0.83 | MRGPRX4 (0.56) | MRGPRX4TP53PKMNFKB1NFKB2 | |
| SCHEMBL27980684 | 0.83 | CYP4F2 (0.64) | SMN1; SMN2RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8466199-B2 | Allyloxy and alkyloxy benzoic acid delivery agents | EMISPHERE TECHNOLOGIES, INC. (US) | 2013-06-18 | — | — | US | disclosed |
| US-8466199-B2 | Allyloxy and alkyloxy benzoic acid delivery agents | EMISPHERE TECHNOLOGIES, INC. (US) | 2013-06-18 | — | — | US | disclosed |
| US-8466199-B2 | Allyloxy and alkyloxy benzoic acid delivery agents | EMISPHERE TECHNOLOGIES, INC. (US) | 2013-06-18 | — | — | US | disclosed |
| US-20100105604-A1 | ALLYLOXY AND ALKYLOXY BENZOIC ACID DELIVERY AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| US-20100105604-A1 | ALLYLOXY AND ALKYLOXY BENZOIC ACID DELIVERY AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| US-20100105604-A1 | ALLYLOXY AND ALKYLOXY BENZOIC ACID DELIVERY AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| EP-2136624-A1 | ALLYLQXY AND ALKYLOXY BENZOIC ACID DELIVERY AGENTS | Emisphere Technologies, Inc. (US) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008116141-A1 | ALLYLQXY AND ALKYLOXY BENZOIC ACID DELIVERY AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008116141-A1 | ALLYLQXY AND ALKYLOXY BENZOIC ACID DELIVERY AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2008-09-25 | — | — | WO | disclosed |
| EP-0764159-B1 | C -4 AMIDE SUBSTITUTED COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | SMITHKLINE BEECHAM PLC (GB) | 2000-08-09 | — | — | EP | disclosed |
| US-5843989-A | C4 -amide substituted compounds and their use as therapeutic agents | SMITHKLINE BEECHAM P.L.C. (GB) | 1998-12-01 | — | — | US | disclosed |
| EP-0764159-A1 | C -4 AMIDE SUBSTITUTED COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | SMITHKLINE BEECHAM PLC (GB) | 1997-03-26 | — | — | EP | disclosed |
| WO-1995034547-A1 | C-4 AMIDE SUBSTITUTED COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | SMITHKLINE BEECHAM PLC (GB) | 1995-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105604-A1 | ALLYLOXY AND ALKYLOXY BENZOIC ACID DELIVERY AGENTS | ABCB11, TSPO, AADAC | MRGPRX4 780/4885TP53 3987/4885PKM 3674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.